

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Glioma	Not applicable	<p>Cell-based and mouse studies suggest a chimeric vesicular stomatitis virus (VSV)-based oncolytic virus could help treat glioma. The VSV glycoprotein in wild-type VSV was replaced with a variant glycoprotein from lymphocytic choriomeningitis virus to create rVSV(GP). In multiple tumor cell lines, rVSV(GP) had cytotoxic potency comparable to that of wild-type VSV. In mice, rVSV(GP) did not elicit neurotoxicity associated with wild-type VSV. In a mouse model of human glioma, rVSV(GP) increased survival compared with wild-type VSV. Next steps could include IND-enabling safety studies.</p> <p><b>SciBX 7(24); doi:10.1038/scibx.2014.703</b>                      Published online June 19, 2014</p>	Patent and licensing status unavailable	<p>Muik, A. <i>et al. Cancer Res.</i>; published online May 8, 2014; doi:10.1158/0008-5472.CAN-13-3306  <b>Contact:</b> Dorothee von Laer, Medical University Innsbruck, Innsbruck, Austria                      e-mail: <a href="mailto:dorothee.von-laer@i-med.ac.at">dorothee.von-laer@i-med.ac.at</a></p>